3900 – Anti-ASGPR

Highlights

• Microtiter plate coated with ASGPR antigens detects patient antibodies.
• Peroxidase-conjugated secondary antibody produces a color signal.
• Detects ASGPR autoantibodies in up to 76% of AIH patients.
• Peroxidase-conjugated secondary antibody produces a color signal.
• Semi-quantitative ELISA for IgG antibodies against ASGPR in human serum.
• Supports diagnosis of autoimmune liver disorders: AIH, PBC, PSC.

Intended Use

The Anti-ASGPR is a semi-quantitative enzyme-linked immunoassay (ELISA) for the determination of IgG antibodies against asialoglycoprotein receptor (ASGPR) in human serum. The Anti-ASGPR is intended as an aid in the diagnosis of systemic liver autoimmune disorders in conjunction with other clinical and laboratory findings. It provides reliable detection of ASGPR antibodies, which are clinically relevant markers of autoimmune liver disease, including autoimmune hepatitis (AIH). The assay helps distinguish autoimmune liver disorders from viral, toxic, or other chronic inflammatory liver conditions. Clinicians can also use it to monitor disease progression and response to therapy, as antibody levels typically decline with effective treatment. This information supports timely and accurate clinical decisions and can guide patient management and therapeutic interventions. The immunoassay is designed for manual professional in vitro diagnostic use.

Diagnostic Relevance

The level of ASGPR, a liver specific membrane receptor playing a pivotal role in the endocytosis of glycoproteins from the blood, correlates with the severity of inflammatory liver disorders, especially autoimmune hepatitis, and declines under therapy. Autoimmune liver diseases include autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). These are distinct disease entities with different clinical and serological characteristics. Patients with AIH frequently produce a variety of autoantibodies. Determination of autoantibodies to ASGPR is used in the follow-up and differential diagnosis of toxic and other chronic inflammatory liver disorders, as anti-ASGPR antibodies can be detected in the sera of up to 76% of patients with AIH.